Fiscal Receipts

Senate LDA lobbying filing

TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY)

Registrant: TIBER CREEK GROUP Year: 2026 Period: First Quarter Type: Q1

View on lda.senate.gov ↗

Reported income

$80.0K

Reported expenses

not reported

Tracked program mentions1

Quoted activity text is clipped to a short extract; each filing’s full description is under Lobbying activities below.

Lobbying activities3

  • Copyright/Patent/TrademarkCPT

    Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act.

  • Health IssuesHCR

    Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025; Issues related to FDA guidance on Alcohol Use Disorder (AUD).

  • Medicare/MedicaidMMM

    Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).

Lobbyists5

  • COREY MALMGREN
  • EMILY KIRLIN
  • JOHN GONZALEZ
  • JONATHON JONES
  • TIMOTHY MOLINO

Source: U.S. Senate Lobbying Disclosure Act database. Dollar figures (underlined) cite the filing record on lda.senate.gov — click to view the citation. Amounts shown as “not reported” are absent from the filing itself.